In this nonrandomized clinical trial, neoadjuvant exercise therapy was well tolerated, with doses 225 to 375 minutes per week showing promising activity in treatment-naive localized prostate cancer. https://ja.ma/3Lw6Pqs
JAMA Oncology
Book and Periodical Publishing
Chicago, Illinois 34,893 followers
A member of the JAMA Network, which includes JAMA, 11 specialty journals, and JAMA Network Open.
About us
JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives more than 6.4 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's HINARI program. JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. The journal’s acceptance rate is 13%. The median time to first decision is 2 days, and 50 days with review. The Journal Impact Factor is 28.4, one of the highest ranking among oncology journals. All articles are published online first. Mary L. (Nora) Disis, MD, Director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health, is the editor in chief.
- Website
-
https://jamanetwork.com/journals/jamaoncology
External link for JAMA Oncology
- Industry
- Book and Periodical Publishing
- Company size
- 5,001-10,000 employees
- Headquarters
- Chicago, Illinois
- Founded
- 2015
- Specialties
- Oncology
Updates
-
Cross-sectional study found that only 4% of cancer survivors fully adhered to current ACS recommendations, with the mean number of guidelines met being 2.0. https://ja.ma/3LgptCq
-
This cohort study assesses the increase in second primary malignant neoplasms and T-cell malignant neoplasm cases associated with chimeric antigen receptor–T cells. https://ja.ma/3VAovpq
-
This Consensus Statement summarizes new evidence-based recommendations and reaffirms standards for timely initial management of BRAF V600E-variant anaplastic thyroid cancer. https://ja.ma/3S4cYhf
Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer
jamanetwork.com
-
Progression-free survival and overall survival benefits of adding chemotherapy to gefitinib were sustained at 5 years, confirming earlier results reported at median follow-up of 17 months. https://ja.ma/3zJ4AwY
-
Viewpoint discusses the end point analyses and results of the RACICALS-RT study. https://ja.ma/3xJDi9s
Postoperative Management of Prostate Cancer
jamanetwork.com
-
Measurable residual disease in patients with chronic lymphocytic leukemia was found to be associated with progression-free survival, especially in the first-line treatment setting and with time-limited therapy. https://ja.ma/3VXYLn7
-
Most viewed in the last 7 days from JAMA Oncology: What is the association of selective pancreatic cancer surveillance with survival? https://ja.ma/4cT7uxA
-
Waterpipe tobacco smoking alone or in combination with cigarette smoking was associated with an increased risk of cancer death due to liver cancer, lung cancer, nasopharyngeal carcinoma, and stomach cancer. https://ja.ma/3Ljra1M
-
In patients with node-positive breast cancer, axillary recurrence after omission of axillary lymph node dissection was rare with no difference by type of surgery (sentinel lymph node biopsy with dual-tracer mapping vs targeted axillary dissection). https://ja.ma/3XYTvCn